Nutritional support in hospitalised patients with diabetes and risk for malnutrition: a secondary analysis of an investigator-initiated, Swiss, randomised controlled multicentre trial

被引:0
|
作者
Keller, Bettina [1 ]
Wunderle, Carla [1 ]
Tribolet, Pascal [1 ]
Stanga, Zeno [2 ]
Kaegi-Braun, Nina [3 ]
Mueller, Beat [4 ,5 ]
Schuetz, Philipp [1 ]
机构
[1] Kantonsspital Aarau AG, Aarau, Switzerland
[2] Univ Bern, Fac Med, Bern, Switzerland
[3] Karolinska Inst, Stockholm, Sweden
[4] Univ Basel, Med Fac, Dept Clin Res, Basel, Switzerland
[5] Cantonal Hosp Aarau, Med Univ Dept, Clin Endocrinol, Aarau, Aargau, Switzerland
来源
BMJ OPEN | 2024年 / 14卷 / 08期
基金
瑞士国家科学基金会;
关键词
Nutritional support; NUTRITION & DIETETICS; Randomized Controlled Trial; DIABETES & ENDOCRINOLOGY; MEDICAL INPATIENTS; CLINICAL-OUTCOMES; MELLITUS; PREVALENCE; INFECTION; FORMULAS; COVID-19; PEOPLE; OLDER;
D O I
10.1136/bmjopen-2024-084754
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The main objective of this study was to investigate the effects of nutritional support on mortality in hospitalised patients with diabetes and nutritional risk participating in the Effect of early nutritional support on Frailty, Functional Outcomes, and Recovery of malnourished medical inpatients Trial (EFFORT) trial. Design Secondary analysis of a Swiss-wide multicentre, randomised controlled trial. Participants Patients with diabetes and risk for malnutrition. Interventions Individualised nutritional support versus usual care. Primary outcome measure 30-day all-cause mortality. Results Of the 2028 patients included in the original trial, 445 patients were diagnosed with diabetes and included in this analysis. In terms of efficacy of nutritional therapy, there was a 25% lower risk for mortality in patients with diabetes receiving nutritional support compared with controls (7% vs 10%, adjusted HR 0.75 (95% CI 0.39 to 1.43)), a finding that was not statistically significant but similar to the overall trial effects with no evidence of interaction (p=0.92). Regarding safety of nutritional therapy, there was no increase in diabetes-specific complications associated with nutritional support, particularly there was no increase in risk for hyperglycaemia (adjusted OR 0.97, 95% CI 0.56 to 1.67 p=0.90). Conclusion Patients with diabetes and malnutrition in the hospital setting have a particularly high risk for adverse outcomes and mortality. Individualised nutritional support reduced mortality in this secondary analysis of a randomized trial, but this effect was not significant calling for further large-scale trials in this vhighly ulnerable patient population.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Cost analysis of a peer support programme for patients with type 2 diabetes: a secondary analysis of a controlled trial
    Johansson, Tim
    Keller, Sophie
    Soennichsen, Andreas C.
    Weitgasser, Raimund
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2017, 27 (02): : 256 - 261
  • [42] IMPACT OF METHOTREXATE ON DISEASE PATTERN IN ACTIVE PSORIATIC ARTHRITIS PATIENTS ELIGIBLE FOR A RANDOMIZED CLINICAL TRIAL WITH USTEKINUMAB: COMPARATIVE BASELINE DATA FROM MULTICENTRE INVESTIGATOR-INITIATED MUST TRIAL
    Rossmanith, T.
    Koehm, M.
    Kiltz, U.
    Rech, J.
    Burmester, G. R.
    Kellner, H.
    Bulczak-Schadendorf, A.
    Foldenauer, A. C.
    Burkhardt, H.
    Behrens, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 773 - 773
  • [43] Individualised Nutritional Supplementation Improves Quality Of Life In Elderly Patients Hospitalised With Acute Stroke; A Randomised Controlled Trial
    Ha, Lisa
    Hauge, Truls
    Iversen, Per O.
    STROKE, 2009, 40 (04) : E237 - E238
  • [44] Peer support for patients with type 2 diabetes: cluster randomised controlled trial
    Smith, S. M.
    Paul, G.
    Kelly, A.
    Whitford, D. L.
    O'Shea, E.
    O'Dowd, T.
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 342 : 482
  • [45] TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
    Pfeiffer, Per
    Yilmaz, Mette
    Moller, Soren
    Zitnjak, Daniela
    Krogh, Merete
    Petersen, Lone Norgard
    Poulsen, Laurids Ostergaard
    Winther, Stine Braendegaard
    Thomsen, Karina Gravgaard
    Qvortrup, Camilla
    LANCET ONCOLOGY, 2020, 21 (03): : 412 - 420
  • [46] Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
    Goldsmith, Scott R.
    Covut, Fahrettin
    Fiala, Mark
    Xiang, Zhifu
    Iqbal, Zahid
    Moore, Nathan
    Bradtke, Elizabeth
    Christen, Brandon
    Rettig, Michael P.
    Christ, Stephanie
    Gehrs, Leah
    Street, Emily
    Wallace, Nicholas
    Ritchey, Julie
    Gao, Feng
    Pachter, Jonathan
    Parikh, Bijal
    Dubberke, Erik R.
    Dipersio, John F.
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (11):
  • [47] Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)—a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy
    Rasmus Ehrenfried Berthelsen
    Sisse Rye Ostrowski
    Morten Heiberg Bestle
    Per Ingemar Johansson
    Critical Care, 23
  • [48] Long-term impact of a nurse-led, home-based, prevention program for hospitalised cardiac patients on risk of secondary events: the multicentre young @ heart randomised controlled trial
    Stewart, S.
    Carrington, M. J.
    Chan, Y. K.
    Calderone, A.
    Goldstein, S.
    Scuffham, P.
    EUROPEAN HEART JOURNAL, 2012, 33 : 443 - 444
  • [49] Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)-a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy
    Berthelsen, Rasmus Ehrenfried
    Ostrowski, Sisse Rye
    Bestle, Morten Heiberg
    Johansson, Per Ingemar
    CRITICAL CARE, 2019, 23 (01)
  • [50] Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trial
    Schmidt, Constantin
    Zapf, Antonia
    Ozga, Ann-Kathrin
    Canbay, Ali
    Denzer, Ulrike
    De Toni, Enrico N.
    Lohse, Ansgar W.
    Schulze, Kornelius
    Roesch, Thomas
    Stein, Alexander
    Wege, Henning
    von Felden, Johann
    BMC CANCER, 2024, 24 (01)